prof. dr. M.S. de Bruin-Weller

prof. dr. M.S. de Bruin-Weller

Full Professor
prof. dr. M.S. de Bruin-Weller
  • Dermatology and Allergology

Research Programs

Infection & Immunity



Marjolein de Bruin-Weller  is a dermatologist and full professor in atopic dermatitis and head of the National Expertise Center of Atopic Dermatitis,  situated  in the dpt. of Dermatology and Allergology of the University Medical Center of Utrecht, The Netherlands


After her training in physiotherapy (1979-1983), she started her medical training at the University of Leiden and graduated in 1990. After this she started as a PhD candidate at Astmacenter Heideheuvel, Hilversum, the Netherlands, supervised by Professor Jan de Monchy (allergologist  University Medical Center Groningen, Professor Henk Jansen (pulmonologist University Medical Center Amsterdam) and dr. Frank Weller (pulmonologist University Medical Center Amsterdam).  In 1997 she defended her PhD thesis “Dynamics of the allergic reaction in the airways and the skin”  at the University of Groningen.


She started her training in dermatology in 1997 at the department of Dermatology/Allergology of the University Medical Center Utrecht and became a staff member at this department in 2001, with a special focus on atopic dermatitis.  In October 2018 she was appointed as Associate Professor and in December 2021 as full professor in atopic dermatitis.

Her major interest is clinical and translational research in atopic dermatitis. She is principle investigator in several clinical trials and investigator-initiated studies focused on difficult to treat atopic dermatitis and systemic immunosuppressive and immuno-modulating treatment. For translational, she closely collaborates with the Center of Translational Immunology in Utrecht (Professor Femke van Wijk).

Together with Femke van Wijk, Marjolein de Bruin leads the Utrecht Atopic Dermatitis Research Group.


In 2018 she imitated  the BioDay Registry in the Netherlands together with dr. Marie-Louise Schuttelaar from the department of Dermatology of the University Medical Center of Groningen. This register is focused on new systemic treatments in atopic dermatitis and includes a lot of data concerning atopic dermatitis (signs, symptoms, quality of life, work impairment) as well as data concerning atopic co-morbidities. At the end of 2021, 14 centers in the Netherlands are participating in the BioDay Registry and   >1000 patients are included.


Marjolein de Bruin-Weller  is a member of the Expertise group Allergy and Eczema Dutch Society of Dermatology and Venereology),  the  European Task Force of Atopic Dermatitis  (ETFAD) , the International Eczema Council (IEC)  and the  GA²LEN ADCARE Task Force.  She is chair of the advisory board Dutch Patient Society for Atopic Dermatitis (VMCE).




Side Activities

External activities (non paid)

Chair Advisory board Dutch patient society for atopic dermatitis (VMCE)

ExComm Member GA²LEN

Member Steering committee of the ADCARE Task Force

Member Dutch Society of Dermatology and Venereology (NVDV)

Member European Academy of Dermatology and Venereology (EADV)

Member European Task Force of Atopic Dermatitis (ETFAD)

Member International Eczema Council (IEC)

Member Horizonscan inflammatory diseases (Zorginstituut Nederland)

Member “ geneesmiddelencommissie FMS”

Chair working group “dure geneesmiddelen” NVDV


Collaboration pharmaceutical industry (paid)

International advisory board member:

AbbVie, Almirall, Arena, Aslan, Eli Lilly, Galderma, Janssen, Leo Pharma, Pfizer, Regeneron, Sanofi-Genzyme

National advisory board member:

AbbVie, Eli Lilly, Galderma, Leo Pharma, Pfizer, and Sanofi-Genzyme


AbbVie, Almirall, Leo Pharma, Eli Lilly, Galderma, Pfizer, Regeneron, and Sanofi- Genzyme


AbbVie, Almirall, Eli Lilly, Galderma, LeoPharma, Pfizer, Regeneron, and Sanofi- Genzyme

 Investigator Initiated Studies:

AbbVie, Leo Pharma, Eli-Lilly, Regeneron and Sanofi-Genzyme

Research Output (170)

Biologicals for pediatric patients with atopic dermatitis:practical challenges and knowledge gaps

van der Rijst Lisa P., van Royen-Kerkhof Annet, Pasmans Suzanne G.M.A., Schappin Renske, de Bruin-Weller Marjolein S., de Graaf Marlies Dec 2023, In: Journal of Dermatological Treatment. 34

Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis

Boesjes Celeste M, van der Gang Lian F, Bakker Daphne S, Ten Cate Tess A, Spekhorst Lotte S, de Graaf Marlies, van Dijk Marijke R, de Bruin-Weller Marjolein S 18 Oct 2023, In: JAMA Dermatology. 159 , p. 1240-1247 8 p.

Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity:a large pragmatic daily practice study from the BioDay registry

Spekhorst Lotte S, Boesjes Celeste M, Loman Laura, Zuithoff Nicolaas P A, Bakker Daphne S, Kamphuis Esmé, Kamsteeg Marijke, Haeck Inge, Oosting Albert J, van Lumig Paula P M, van Lynden-van Nes Anneke M T, Tupker Ron A, Flinterman Annebeth, Garritsen Floor M, Touwslager Wouter R H, de Bruin-Weller Marjolein S, Schuttelaar Marie-Louise, de Graaf Marlies 13 May 2023, In: British Journal of Dermatology. 189 , p. 327-335 9 p.

Limited excretion of dupilumab into breastmilk:A case report

Dekkers Coco, El Amrani Mohsin, van Luin Matthijs, Bakker Daphne, Plusjé Leon, van Wijk Femke, de Bruin-Weller Marjolein 5 May 2023, In: JEADV : journal of the European Academy of Dermatology and Venereology. 37 , p. e1154-e1155

Biological Tipping Point in Patients with Atopic Dermatitis Treated with Different Dosing Intervals of Dupilumab

Dekkers Coco, van der Wal M Marlot, El Amrani Mohsin, van Luin Matthijs, Bakker Daphne S, de Bruin-Weller Marjolein, van Wijk Femke 28 Mar 2023, In: Journal of Investigative Dermatology. 143 , p. 1822-1825.e3

Dupilumab-associated ocular surface disease in atopic dermatitis patients:clinical characteristics, ophthalmic treatment response, and conjunctival goblet cell analysis

Achten Roselie, Thijs Judith, van der Wal Marlot, van Luijk Chantal, de Graaf Marlies, Bakker Daphne, de Boer Joke, van Wijk Femke, de Bruin-Weller Marjolein 19 Mar 2023, In: Allergy. 78 , p. 2266-2276 11 p.

The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis

Spekhorst Lotte S, de Graaf Marlies, van der Rijst Lisa P, Zuithoff Nicolaas P A, Schweizer René C, Kamsteeg Marijke, Haeck Inge, van Lynden-van Nes Anneke M T, van Lumig Paula, Romeijn Geertruida L E, Schuttelaar Marie-Louise, de Bruin-Weller Marjolein S Jan 2023, In: Clinical and Translational Allergy. 13 4 p.

Biomarkers in atopic dermatitis

Bakker Daphne, de Bruin-Weller Marjolein, Drylewicz Julia, van Wijk Femke, Thijs Judith 2023, In: Journal of Allergy and Clinical Immunology. 151 , p. 1163-1168 6 p.

Dupilumab in daily practice for the treatment of pediatric atopic dermatitis:28-week clinical and biomarker results from the BioDay registry

Kamphuis Esmé, Boesjes Celeste M., Loman Laura, Bakker Daphne S., Poelhekken Mila, Zuithoff Nicolaas P.A., Kamsteeg Marijke, Romeijn Geertruida L.E., van Wijk Femke, de Bruin-Weller Marjolein S., de Graaf Marlies, Schuttelaar Marie L.A. 5 Dec 2022, In: Pediatric Allergy and Immunology. 33

Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis:Results from the BioDay Registry

Boesjes Celeste M., Kamphuis Esmé, Zuithoff Nicolaas P.A., Bakker Daphne S., Loman Laura, Spekhorst Lotte S., Haeck Inge, Kamsteeg Marijke, VAN LYNDEN-VAN NES Anneke M.T., Garritsen Floor M., Politiek Klaziena, Oldhoff Marja, DE GRAAF Marlies, Schuttelaar Marie L.A., DE BRUIN-WELLER Marjolein S. 24 Nov 2022, In: Acta Dermato-Venereologica. 102

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical uses cookies

This website uses cookies This website displays videos from, among others, YouTube. Such parties place cookies (third-party cookies). If you do not want these cookies, you can indicate that here. We also place cookies ourselves to improve our site.

Read more about the cookie policy

Agree No, rather not